Anti-tumor analysis of the RIG-I agonist in vitro and in vivo

IF 2.2 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemistry and Biophysics Reports Pub Date : 2025-09-12 DOI:10.1016/j.bbrep.2025.102249

Qian Wang , Ziyang Song , Bopei Cui , Chaoqiang An , Fan Gao , Mingchen Liu , Lu Li , Xiao Ma , Xing Wu , Zhenglun Liang

引用次数: 0

Abstract

Retinoic acid-inducible gene I (RIG-I), a key pattern recognition receptor (PRR) detecting cytosolic 5′-triphosphorylated double-stranded RNA (5′-ppp dsRNA), mediated antitumor immunity. Here, we evaluated RIG-I agonists as potential antitumor agents. To analyze the anti-tumor efficacy, we engineered a panel of 5′-PPP-modified stem-loop-structured RNAs leveraging the non-coding sequence of SARS-CoV-2. Through systematic screening, nCoV-L emerged as a potent RIG-I agonist that induced death in hepatocellular carcinomas (HCC), pulmonary carcinomas, and colorectal cancer (CRC) in vitro and suppressed tumor growth in vivo. Mechanistic studies demonstrated that nCoV-L elicited mitochondria-dependent apoptosis, supporting its potential as a broad-spectrum antitumor agent.

查看原文本刊更多论文

rig - 1激动剂体内外抗肿瘤分析

视黄酸诱导基因I （RIG-I）是检测胞质5 ' -三磷酸化双链RNA （5 ' -ppp dsRNA）的关键模式识别受体（PRR），介导抗肿瘤免疫。在这里，我们评估了rig - 1激动剂作为潜在的抗肿瘤药物。为了分析抗肿瘤效果，我们利用SARS-CoV-2的非编码序列设计了一组5 ' - ppp修饰的茎环结构rna。通过系统筛选，nCoV-L成为一种有效的rig - 1激动剂，在体外诱导肝细胞癌（HCC）、肺癌和结直肠癌（CRC）死亡，并在体内抑制肿瘤生长。机制研究表明，nCoV-L引发线粒体依赖性细胞凋亡，支持其作为广谱抗肿瘤药物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemistry and Biophysics Reports Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

4.60

自引率

0.00%

发文量

191

审稿时长

59 days

期刊介绍： Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.